DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l298pk/option_and) has announced the addition of the "Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering.
The Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor offers a right to option and evaluation the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all option and evaluation deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in option and evaluation dealmaking
Chapter 3 - Overview of option and evaluation deal structure
Chapter 4 - Leading option and evaluation deals
Chapter 5 - Big pharma option and evaluation deals
Chapter 6 - Big biotech option and evaluation deals
Chapter 7 - Option and evaluation contracts directory
- Aspen Pharmacare
- Baxter International
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Eli Lilly
- Gilead Sciences
- Johnson & Johnson
- Merck & Co
- Mitsubishi Tanabe
- Novo Nordisk
For more information visit http://www.researchandmarkets.com/research/l298pk/option_and